Shanghai Henlius Biotech Inc
HKEX:2696
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.5
23.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Gross Margin
Shanghai Henlius Biotech Inc
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | CN |
| Market Cap | 13B HKD |
| Gross Margin |
73%
|
| Country | FR |
| Market Cap | 6T USD |
| Gross Margin |
0%
|
| Country | US |
| Market Cap | 310.2B USD |
| Gross Margin |
67%
|
| Country | US |
| Market Cap | 142B USD |
| Gross Margin |
60%
|
| Country | US |
| Market Cap | 115B USD |
| Gross Margin |
78%
|
| Country | US |
| Market Cap | 101.6B USD |
| Gross Margin |
86%
|
| Country | US |
| Market Cap | 94.1B EUR |
| Gross Margin |
76%
|
| Country | AU |
| Market Cap | 134.4B AUD |
| Gross Margin |
52%
|
| Country | US |
| Market Cap | 78.5B USD |
| Gross Margin |
87%
|
| Country | US |
| Market Cap | 39.3B EUR |
| Gross Margin |
75%
|
| Country | NL |
| Market Cap | 36B EUR |
| Gross Margin |
89%
|
Shanghai Henlius Biotech Inc
Glance View
In the heart of China's bustling financial district, Shanghai Henlius Biotech Inc. stands proud as a beacon of innovation in the biopharmaceutical industry. Founded in 2010, Henlius has rapidly grown to become a notable player in the development of monoclonal antibodies, with a focus on oncology, autoimmune disorders, and ophthalmic conditions. The company's business model is rooted in its robust research and development capabilities, which are supported by strategic partnerships and a dedicated pipeline. By harnessing state-of-the-art technology and a global talent pool, Henlius crafts biosimilar and innovative biological drugs designed to meet the escalating health needs across the globe. With a strong focus on cutting-edge R&D, they have successfully commercialized several key products that have gained regulatory approval, allowing them to penetrate both domestic and international markets. Revenue flows into Henlius through a diversified portfolio that stretches beyond drug development to encompass manufacturing and sales partnerships. By leveraging their fully-integrated biopharmaceutical platform, Henlius not only develops its proprietary medications but also collaborates with other pharmaceutical giants to bring products to market efficiently. These collaborations often translate into licensing agreements and royalties, which provide Henlius with recurring income streams. The company's ability to navigate complex regulatory environments and its strategic expansion into global markets – including Europe, Southeast Asia, and Latin America – further reinforces its revenue-generating capacity. Thus, Henlius stands as a testament to the power of strategic ingenuity and cutting-edge science in the ever-evolving landscape of global healthcare.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Shanghai Henlius Biotech Inc's most recent financial statements, the company has Gross Margin of 73.2%.
You don't have any saved screeners yet
